Search filters

List of works by Peter F Thall

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

scientific article published on 01 November 2020

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

scientific article

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

scientific article

Bayesian adaptive model selection for optimizing group sequential clinical trials

scientific article published on November 2008

Bayesian designs to account for patient heterogeneity in phase II clinical trials

scientific article published on July 2008

Bayesian nonparametric statistics: A new toolkit for discovery in cancer research.

scientific article

Bayesian treatment comparison using parametric mixture priors computed from elicited histograms.

scientific article published in January 2017

Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

scientific article published on 11 October 2010

Comparing Bayesian early stopping boundaries for phase II clinical trials

scientific article published on 27 July 2020

Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation

scientific article published on 15 May 2015

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

scientific article published on 22 March 2019

Continuous Bayesian adaptive randomization based on event times with covariates

scientific article published in January 2006

Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study ⬇️

scientific article published on December 7, 2012

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

scientific article published on 20 May 2016

Durable remission with salvage second autotransplants in patients with multiple myeloma

scientific article

Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.

scientific article published on 3 July 2003

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

scientific article published in June 2002

High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation

scientific article

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies

scientific article

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

scientific article published on 22 July 2018

Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data

scientific article published on 09 April 2019

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

scientific article

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation

scientific article published on 13 April 2015

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

scientific article published on July 2016

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

scientific article

Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery

scientific article published on 30 March 2020

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

scientific article

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

scientific article published on 8 April 2004

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

scientific article

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma

scientific article published on 02 March 2018

Practical Bayesian adaptive randomisation in clinical trials

scientific article published on 16 February 2007

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

scientific article

Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer

scientific article published on 03 August 2012

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia

scientific article published on September 2009

Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS

scientific article published on 10 December 2018

Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination

scientific article published on 15 August 2018

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution

article by Joshua N Kellner et al published 2 November 2018 in Oncotarget

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

scientific article published on 01 February 2020

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size ⬇️

scientific article published on May 2, 2013

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

scientific article published on 10 June 2015

Paulina is supported by:

About Paulina

Help